We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDNL
RNS Number : 1481Q
Diurnal Group PLC
07 September 2017
7 September 2017
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that Non-Executive Director, John Goddard, has acquired 10,791 recently vested shares at GBP0.05 per share.
As published in the Company's AIM Admission Document, published on 21 December 2015, and in connection with his recruitment, John Goddard was awarded 32,374 ordinary shares of GBP0.05 each for which Mr Goddard will pay the nominal value for each share. The award of shares vest in thirds 18, 24 and 36 months from 24 December 2015, being the date of admission to AIM. There are no other performance criteria.
John Goddard's interest in the Company is now as follows:
Name Position Total number of conditional shares Total number of ordinary shares now now held held -------------- ------------------------ ------------------------------------- ------------------------------------- John Goddard Non-Executive Director 21,583 26,983 -------------- ------------------------ ------------------------------------- ------------------------------------- For further information, please visit www.diurnal.co.uk or contact: +44 (0)20 3727 Diurnal Group plc 1000 Martin Whitaker, Chief Executive Officer Richard Bungay, Chief Financial Officer Numis Securities Ltd (Nominated +44 (0)20 7260 Adviser) 1000 Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield Corporate Broking: James Black Panmure Gordon (UK) Limited (Joint +44 (0) 20 7886 Broker) 2500 Corporate Finance: Freddy Crossley / Duncan Monteith Corporate Broking: Tom Salvesen +44 (0)20 3727 FTI Consulting 1000 Simon Conway Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
1 Details of the person discharging managerial responsibilities / person closely associated ---- ----------------------------------------------------------------- a) Name John Goddard ---- ------------------------------ --------------------------------- 2 Reason for the notification ---- ----------------------------------------------------------------- a) Position/status Non-Executive Director ---- ------------------------------ --------------------------------- b) Initial notification Initial notification /Amendment ---- ------------------------------ --------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ----------------------------------------------------------------- a) Name Diurnal Group plc ---- ------------------------------ --------------------------------- b) LEI n/a ---- ------------------------------ --------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ----------------------------------------------------------------- a) Description of Ordinary shares of 5p each the financial instrument, type of instrument ---- Identification GB00BDB6Q760 code b) Nature of the Purchase of shares transaction ---- ------------------------------ --------------------------------- c) Price(s) and volume(s) ---- -------------- -------------- Price(s) Volume(s) ---- -------------- -------------- GBP0.05 10,791 -------------------------------------------------- -------------- d) Aggregated information ---- - Aggregated volume 10,791 - Price GBP539.55 e) Date of the transaction 7 September 2017 ---- ------------------------------ --------------------------------- f) Place of the transaction London Stock Exchange, AIM ---- ------------------------------ ---------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFEVAIIDIID
(END) Dow Jones Newswires
September 07, 2017 09:51 ET (13:51 GMT)
1 Year Diurnal Chart |
1 Month Diurnal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions